BostonGene Announces Collaboration to Evaluate Biomarkers for Colorectal Cancer and Multiple Myeloma Using AI-Driven Molecular Profiling in Clinical Trials

BostonGene, a leader in AI-driven molecular and immune profiling that accelerates drug development and personalizes patient care, today announced a strategic collaboration with Johnson & Johnson aimed at accelerating progress in precision cancer treatment. This collaboration seeks to combine the expertise and resources of both organizations to drive advancements in oncology research and personalized treatment strategies.

The partnership reflects BostonGene’s commitment to improving patient outcomes through innovative research and data-driven approaches. By focusing on advanced biomarker analysis, the collaboration will enhance patient stratification and treatment selection for both metastatic colorectal cancer and multiple myeloma clinical trials. Additionally, BostonGene’s AI-powered molecular analytics will provide deeper insights into treatment responses and identify predictive biomarkers to help inform therapeutic decisions in the future. These efforts will aim to advance precision medicine approaches and in turn, to benefit clinicians, researchers and patients.

“This partnership allows us to leverage our AI-driven technologies for a more comprehensive understanding of cancer biology,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Incorporating advanced AI-driven multiomics analysis into drug development is essential to improving the precision and effectiveness of cancer care.”